Via EFS-Web

Attorney Docket No.: 1759.051A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Benameur et al.

Examiner:

Aradhana Sasan

Filed:

January 23, 2004

Group Art Unit:

1609

Serial No.:

10/764,282

Docket No.:

1759.051A

Title:

PHARMACEUTICAL COMPOSITION FOR ORAL USE COMPRISING

AN ACTIVE PRINCIPLE LIABLE TO UNDERGO A LARGE FIRST

INTESTINAL PASSAGE EFFECT

Confirmation No.: 9192

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dated: November 5, 2007

AMENDMENT AND RESPONSE

Dear Sir:

This is a response to the Final Office Action mailed on July 9, 2007. In light of a request for a 1-month extension and fee therefore, enclosed herewith, a response is required by November 9, 2007. Therefore, this response is timely filed. Applicants are filing a request for continued examination (RCE) under 37 CFR § 1.114 with this response.

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 5.